Acquisition History / BioMarin Pharmaceutical Inc. / Inozyme Pharma, Inc.
BioMarin Pharmaceutical Inc. Acquires Inozyme Pharma, Inc.
Announced May 16, 2025 — $270M
What happened
BioMarin agreed on May 16, 2025 to acquire Inozyme Pharma for $4.00 per share in an all-cash transaction with total consideration of approximately $270M.
- Acquirer
- BioMarin Pharmaceutical Inc.
- Target
- Inozyme Pharma, Inc.
- Announced
- May 16, 2025
- Price
- $270M
- Industry
- Rare disease biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did BioMarin Pharmaceutical Inc. acquire Inozyme Pharma, Inc.?
BioMarin Pharmaceutical Inc. acquired Inozyme Pharma, Inc. on May 16, 2025. This was BioMarin Pharmaceutical Inc.'s 1st publicly tracked acquisition out of 2 we have on record.
How much did BioMarin Pharmaceutical Inc. pay for Inozyme Pharma, Inc.?
BioMarin Pharmaceutical Inc. paid $270M for Inozyme Pharma, Inc..
What does Inozyme Pharma, Inc. do?
BioMarin agreed on May 16, 2025 to acquire Inozyme Pharma for $4.00 per share in an all-cash transaction with total consideration of approximately $270M.
What other Rare disease biotechnology companies has BioMarin Pharmaceutical Inc. acquired?
Inozyme Pharma, Inc. is BioMarin Pharmaceutical Inc.'s only publicly tracked acquisition in Rare disease biotechnology so far.
More BioMarin Pharmaceutical Inc. acquisitions
Amicus Therapeutics, Inc.
$4.80B · 2025